FROM THE LAB
Research & Insights
View all articlesFDA Panel's Peptide Vote: Easier Tesamorelin Access and Off-Label Metabolic Prescribing
An FDA panel vote to ease Tesamorelin access could reshape off-label metabolic prescribing, as research on peptides l...
Read ArticleRetatrutide Compounding Under Scrutiny as FDA Warns on GLP-1 Weight Loss Drugs
Retatrutide compounding faces FDA warnings as demand surges for the triple-hormone agonist. Bibliometric data show a ...
Read ArticleTesamorelin Off-Label Prescribing Looms as FDA Panel Eases Peptide Access
Tesamorelin off-label prescribing surges after an FDA panel vote eases peptide access. Researchers explore visceral-f...
Read Article